company background image
PBH

Prestige Consumer Healthcare NYSE:PBH Stock Report

Last Price

US$60.26

Market Cap

US$3.0b

7D

5.8%

1Y

17.2%

Updated

06 Jul, 2022

Data

Company Financials +
PBH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health3/6
Dividends0/6

PBH Stock Overview

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally.

Prestige Consumer Healthcare Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prestige Consumer Healthcare
Historical stock prices
Current Share PriceUS$60.26
52 Week HighUS$63.83
52 Week LowUS$50.40
Beta0.58
1 Month Change6.71%
3 Month Change13.02%
1 Year Change17.19%
3 Year Change94.58%
5 Year Change18.44%
Change since IPO239.49%

Recent News & Updates

May 27
Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?

Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

PBHUS PharmaceuticalsUS Market
7D5.8%1.4%0.7%
1Y17.2%10.8%-18.4%

Return vs Industry: PBH exceeded the US Pharmaceuticals industry which returned 10.6% over the past year.

Return vs Market: PBH exceeded the US Market which returned -18.4% over the past year.

Price Volatility

Is PBH's price volatile compared to industry and market?
PBH volatility
PBH Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement12.1%
Market Average Movement8.2%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.4%

Stable Share Price: PBH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PBH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996535Ron Lombardihttps://www.prestigebrands.com

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief.

Prestige Consumer Healthcare Fundamentals Summary

How do Prestige Consumer Healthcare's earnings and revenue compare to its market cap?
PBH fundamental statistics
Market CapUS$3.01b
Earnings (TTM)US$205.38m
Revenue (TTM)US$1.09b

14.6x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PBH income statement (TTM)
RevenueUS$1.09b
Cost of RevenueUS$458.94m
Gross ProfitUS$627.87m
Other ExpensesUS$422.49m
EarningsUS$205.38m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.11
Gross Margin57.77%
Net Profit Margin18.90%
Debt/Equity Ratio93.6%

How did PBH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PBH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBH?

Other financial metrics that can be useful for relative valuation.

PBH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.1x
Enterprise Value/EBITDA12.2x
PEG Ratio2.8x

Price to Earnings Ratio vs Peers

How does PBH's PE Ratio compare to its peers?

PBH PE Ratio vs Peers
The above table shows the PE ratio for PBH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.2x
HRMY Harmony Biosciences Holdings
66.6x43.2%US$3.2b
CORT Corcept Therapeutics
24.9x19.8%US$2.7b
PCRX Pacira BioSciences
68.2x16.7%US$2.7b
AMPH Amphastar Pharmaceuticals
21.2xn/aUS$1.7b
PBH Prestige Consumer Healthcare
14.6x5.3%US$3.0b

Price-To-Earnings vs Peers: PBH is good value based on its Price-To-Earnings Ratio (14.6x) compared to the peer average (45.2x).


Price to Earnings Ratio vs Industry

How does PBH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: PBH is good value based on its Price-To-Earnings Ratio (14.6x) compared to the US Pharmaceuticals industry average (22.1x)


Price to Earnings Ratio vs Fair Ratio

What is PBH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.6x
Fair PE Ratio18.4x

Price-To-Earnings vs Fair Ratio: PBH is good value based on its Price-To-Earnings Ratio (14.6x) compared to the estimated Fair Price-To-Earnings Ratio (18.4x).


Share Price vs Fair Value

What is the Fair Price of PBH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PBH ($60.26) is trading below our estimate of fair value ($153.13)

Significantly Below Fair Value: PBH is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: PBH is poor value based on its PEG Ratio (2.8x)


Discover undervalued companies

Future Growth

How is Prestige Consumer Healthcare forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PBH's forecast earnings growth (5.3% per year) is above the savings rate (1.9%).

Earnings vs Market: PBH's earnings (5.3% per year) are forecast to grow slower than the US market (13% per year).

High Growth Earnings: PBH's earnings are forecast to grow, but not significantly.

Revenue vs Market: PBH's revenue (2.7% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: PBH's revenue (2.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PBH's Return on Equity is forecast to be low in 3 years time (11.9%).


Discover growth companies

Past Performance

How has Prestige Consumer Healthcare performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PBH has high quality earnings.

Growing Profit Margin: PBH's current net profit margins (18.9%) are higher than last year (17.5%).


Past Earnings Growth Analysis

Earnings Trend: PBH's earnings have declined by 2.6% per year over the past 5 years.

Accelerating Growth: PBH's earnings growth over the past year (24.7%) exceeds its 5-year average (-2.6% per year).

Earnings vs Industry: PBH earnings growth over the past year (24.7%) exceeded the Pharmaceuticals industry 19.5%.


Return on Equity

High ROE: PBH's Return on Equity (13%) is considered low.


Discover strong past performing companies

Financial Health

How is Prestige Consumer Healthcare's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PBH's short term assets ($293.3M) exceed its short term liabilities ($143.4M).

Long Term Liabilities: PBH's short term assets ($293.3M) do not cover its long term liabilities ($1.9B).


Debt to Equity History and Analysis

Debt Level: PBH's net debt to equity ratio (91.9%) is considered high.

Reducing Debt: PBH's debt to equity ratio has reduced from 266.5% to 93.6% over the past 5 years.

Debt Coverage: PBH's debt is not well covered by operating cash flow (17.6%).

Interest Coverage: PBH's interest payments on its debt are well covered by EBIT (5.2x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Prestige Consumer Healthcare current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PBH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PBH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PBH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PBH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PBH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Ron Lombardi (58 yo)

7.08yrs

Tenure

US$6,031,517

Compensation

Mr. Ronald M. Lombardi, also known as Ron, served as a Director at Consumer Healthcare Products Association. He has been the Chief Executive Officer and President of Prestige Brands Holdings, Inc. (now Pre...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD6.03M) is about average for companies of similar size in the US market ($USD6.89M).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PBH's management team is considered experienced (5 years average tenure).


Board Members

Experienced Board: PBH's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Prestige Consumer Healthcare Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Prestige Consumer Healthcare Inc.
  • Ticker: PBH
  • Exchange: NYSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$3.008b
  • Shares outstanding: 49.92m
  • Website: https://www.prestigebrands.com

Number of Employees


Location

  • Prestige Consumer Healthcare Inc.
  • 660 White Plains Road
  • Suite 250
  • Tarrytown
  • New York
  • 10591
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/06 00:00
End of Day Share Price2022/07/06 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.